urea has been researched along with Anxiety in 32 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a post hoc analysis, the effect of pimavanserin on anxious depression was determined from CLARITY, a randomized, double-blind, placebo-controlled study in patients with major depression and an inadequate response to previous therapy." | 9.34 | Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. ( Dirks, B; Fava, M; Freeman, MP; Jha, MK; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH, 2020) |
| "We report a successful case of awake intubation in a patient with anxiety neurosis via continuous administration of landiolol and dexmedetomidine." | 7.80 | [Awake intubation with landiolol and dexmedetomidine in a patient with anxiety neurosis]. ( Fujitate, Y; Kitano, M; Komasawa, N; Kuzukawa, Y; Minami, T; Nagamine, T, 2014) |
| "In a post hoc analysis, the effect of pimavanserin on anxious depression was determined from CLARITY, a randomized, double-blind, placebo-controlled study in patients with major depression and an inadequate response to previous therapy." | 5.34 | Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. ( Dirks, B; Fava, M; Freeman, MP; Jha, MK; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH, 2020) |
| "Hyperbilirubinemia was produced by infusing bilirubin 20 mg/kg/h during 3 h into 6-week-old male Sprague-Dawley rats." | 5.27 | Open-field behavior of rats previously subjected to short-term hyperbilirubinemia with or without blood-brain barrier manipulations. ( Bratlid, D; Hansen, TW; Sagvolden, T, 1987) |
| "We report a successful case of awake intubation in a patient with anxiety neurosis via continuous administration of landiolol and dexmedetomidine." | 3.80 | [Awake intubation with landiolol and dexmedetomidine in a patient with anxiety neurosis]. ( Fujitate, Y; Kitano, M; Komasawa, N; Kuzukawa, Y; Minami, T; Nagamine, T, 2014) |
| " In this study, we investigated the role of these hypothalamic neuropeptides in anxiety-like responses of nicotine and stress-induced reinstatement of nicotine-seeking behavior." | 3.76 | Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. ( Berrendero, F; de Lecea, L; Maldonado, R; Martín-García, E; Plaza-Zabala, A, 2010) |
| "The present study assessed the effects of a novel endocannabinoid uptake inhibitor, LY2183240, on anxiety- and alcohol-seeking behaviors in a unique animal model that may represent increased genetic risk to develop co-morbid anxiety and alcohol-use disorders in humans." | 3.76 | Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference. ( Barker, EL; Barrenha, GD; Chester, JA; Mlinac, NS; Powers, MS, 2010) |
| "6 microg/microl) effectively prevented seizures induced by the unilateral GABAergic blockade of Area tempestas (bicuculline, 0." | 3.73 | Anticonvulsant and anxiolytic activity of FrPbAII, a novel GABA uptake inhibitor isolated from the venom of the social spider Parawixia bistriata (Araneidae: Araneae). ( Beleboni, Rde O; Coutinho-Netto, J; Cunha, AO; dos Santos, WF; Gelfuso, EA; Liberato, JL; Mortari, MR, 2006) |
| "In 49 patients receiving continuous ambulatory peritoneal dialysis, we assessed the relative influences of adequacy of dialysis (assessed by kinetic transfer/volume urea) and psychological symptoms (depression and anxiety) upon the patients' evaluation of their overall quality of life (QoL)." | 3.69 | Quality of life in peritoneal dialysis patients. ( Baltimore, D; Finkelstein, FO; Finkelstein, SH; Juergensen, P; Kliger, AS; Steele, TE, 1996) |
| "Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis occurring in Parkinson's disease." | 2.66 | New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin. ( Cannavò, D; Caraci, F; Caruso, G; Drago, F; Leggio, GM; Salomone, S; Santagati, M, 2020) |
| "A rat model of migraine induced by recurrent administration of nitroglycerin (NTG) (5 mg/kg/i." | 1.62 | The involvement of orexin 1 and cannabinoid 1 receptors within the ventrolateral periaqueductal gray matter in the modulation of migraine-induced anxiety and social behavior deficits of rats. ( Abbasnejad, M; Esmaeili-Mahani, S; Kooshki, R; Pourrahimi, AM; Raoof, M, 2021) |
| "Convulsive seizures are due to abnormal synchronous and repetitive neuronal discharges in the central nervous system (CNS)." | 1.46 | SB-334867, an orexin receptor 1 antagonist, decreased seizure and anxiety in pentylenetetrazol-kindled rats. ( Asadi, S; Fereidoni, M; Kordi Jaz, E; Moghimi, A; Roohbakhsh, A; Shamsizadeh, A, 2017) |
| " Pharmacokinetic analysis of several compounds indicated excellent oral bioavailability and a reasonable half-life in rats." | 1.30 | Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality. ( Belonga, KL; Carter, DB; Im, HK; Im, WB; Jacobsen, EJ; Mickelson, JW; Petke, JD; Sethy, VH; Stelzer, LS; Tang, AH; TenBrink, RE; VonVoigtlander, PF; Zhong, WZ, 1999) |
| "Hyperbilirubinemia was produced by infusing bilirubin 20 mg/kg/h during 3 h into 6-week-old male Sprague-Dawley rats." | 1.27 | Open-field behavior of rats previously subjected to short-term hyperbilirubinemia with or without blood-brain barrier manipulations. ( Bratlid, D; Hansen, TW; Sagvolden, T, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (21.88) | 18.7374 |
| 1990's | 4 (12.50) | 18.2507 |
| 2000's | 3 (9.38) | 29.6817 |
| 2010's | 14 (43.75) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Pourrahimi, AM | 1 |
| Abbasnejad, M | 2 |
| Raoof, M | 2 |
| Esmaeili-Mahani, S | 2 |
| Kooshki, R | 1 |
| Salehabadi, S | 1 |
| Abrari, K | 1 |
| Elahdadi Salmani, M | 2 |
| Nasiri, M | 1 |
| Lashkarbolouki, T | 2 |
| Caraci, F | 1 |
| Santagati, M | 1 |
| Caruso, G | 1 |
| Cannavò, D | 1 |
| Leggio, GM | 1 |
| Salomone, S | 1 |
| Drago, F | 1 |
| Papakostas, GI | 1 |
| Fava, M | 1 |
| Freeman, MP | 1 |
| Shelton, RC | 1 |
| Thase, ME | 1 |
| Jha, MK | 1 |
| Trivedi, MH | 1 |
| Dirks, B | 1 |
| Liu, K | 1 |
| Stankovic, S | 1 |
| Bahramzadeh Zoeram, S | 1 |
| Goudarzi, I | 1 |
| Staples, LG | 2 |
| Cornish, JL | 2 |
| Deats, SP | 1 |
| Adidharma, W | 1 |
| Lonstein, JS | 1 |
| Yan, L | 1 |
| Nakamachi, T | 1 |
| Shibata, H | 1 |
| Sakashita, A | 1 |
| Iinuma, N | 1 |
| Wada, K | 1 |
| Konno, N | 1 |
| Matsuda, K | 1 |
| Nagamine, T | 1 |
| Komasawa, N | 1 |
| Fujitate, Y | 1 |
| Kuzukawa, Y | 1 |
| Kitano, M | 1 |
| Minami, T | 1 |
| Vanderhaven, MW | 1 |
| Nowak, Z | 1 |
| Wańkowicz, Z | 1 |
| Laudanski, K | 1 |
| Bahaaddini, M | 1 |
| Khatamsaz, S | 1 |
| Kordi Jaz, E | 1 |
| Moghimi, A | 1 |
| Fereidoni, M | 1 |
| Asadi, S | 1 |
| Shamsizadeh, A | 1 |
| Roohbakhsh, A | 1 |
| Plaza-Zabala, A | 1 |
| Martín-García, E | 1 |
| de Lecea, L | 1 |
| Maldonado, R | 1 |
| Berrendero, F | 1 |
| Powers, MS | 1 |
| Barrenha, GD | 1 |
| Mlinac, NS | 1 |
| Barker, EL | 1 |
| Chester, JA | 1 |
| Scott, MM | 1 |
| Marcus, JN | 1 |
| Pettersen, A | 1 |
| Birnbaum, SG | 1 |
| Mochizuki, T | 1 |
| Scammell, TE | 1 |
| Nestler, EJ | 1 |
| Elmquist, JK | 1 |
| Lutter, M | 1 |
| Johnson, PL | 1 |
| Samuels, BC | 1 |
| Fitz, SD | 1 |
| Lightman, SL | 1 |
| Lowry, CA | 1 |
| Shekhar, A | 1 |
| Rodgers, RJ | 1 |
| Wright, FL | 1 |
| Snow, NF | 1 |
| Taylor, LJ | 1 |
| BARUCCI, M | 1 |
| Lorberbaum, JP | 1 |
| Kose, S | 1 |
| Johnson, MR | 1 |
| Arana, GW | 1 |
| Sullivan, LK | 1 |
| Hamner, MB | 1 |
| Ballenger, JC | 1 |
| Lydiard, RB | 1 |
| Brodrick, PS | 1 |
| Bohning, DE | 1 |
| George, MS | 1 |
| Liberato, JL | 1 |
| Cunha, AO | 1 |
| Mortari, MR | 1 |
| Gelfuso, EA | 1 |
| Beleboni, Rde O | 1 |
| Coutinho-Netto, J | 1 |
| dos Santos, WF | 1 |
| Graham, MR | 1 |
| Davies, B | 1 |
| Kicman, A | 1 |
| Cowan, D | 1 |
| Hullin, D | 1 |
| Baker, JS | 1 |
| Morgan, WK | 1 |
| Kennett, GA | 2 |
| Bailey, F | 1 |
| Piper, DC | 1 |
| Blackburn, TP | 2 |
| Steele, TE | 1 |
| Baltimore, D | 1 |
| Finkelstein, SH | 1 |
| Juergensen, P | 1 |
| Kliger, AS | 1 |
| Finkelstein, FO | 1 |
| Bright, F | 1 |
| Trail, B | 1 |
| Baxter, GS | 1 |
| Jacobsen, EJ | 1 |
| Stelzer, LS | 1 |
| TenBrink, RE | 1 |
| Belonga, KL | 1 |
| Carter, DB | 1 |
| Im, HK | 1 |
| Im, WB | 1 |
| Sethy, VH | 1 |
| Tang, AH | 1 |
| VonVoigtlander, PF | 1 |
| Petke, JD | 1 |
| Zhong, WZ | 1 |
| Mickelson, JW | 1 |
| Hansen, TW | 1 |
| Sagvolden, T | 1 |
| Bratlid, D | 1 |
| Segers, MJ | 1 |
| Mertens, C | 1 |
| Ecanow, B | 1 |
| Gold, BH | 1 |
| Tunkunas, P | 1 |
| Breffeilh, LA | 1 |
| Goldstein, L | 1 |
| Pfeiffer, CC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for urea and Anxiety
| Article | Year |
|---|---|
New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
Topics: Alzheimer Disease; Antipsychotic Agents; Anxiety; Humans; Piperidines; Psychotic Disorders; Quinolon | 2020 |
3 trials available for urea and Anxiety
| Article | Year |
|---|---|
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Depression; Depressive Disorder, Major; | 2020 |
Recombinant human growth hormone in abstinent androgenic-anabolic steroid use: psychological, endocrine and trophic factor effects.
Topics: Adult; Anabolic Agents; Androgens; Anxiety; Blood Glucose; Body Composition; C-Reactive Protein; Dep | 2007 |
Quantitative EEG analysis of single-dose effect relationships in normal volunteers of Pacinox (capuride), a new antianxiety drug.
Topics: Administration, Oral; Adult; Anxiety; Blood Pressure; Brain; Chlordiazepoxide; Clinical Trials as To | 1971 |
28 other studies available for urea and Anxiety
| Article | Year |
|---|---|
The involvement of orexin 1 and cannabinoid 1 receptors within the ventrolateral periaqueductal gray matter in the modulation of migraine-induced anxiety and social behavior deficits of rats.
Topics: Animals; Anxiety; Behavior, Animal; Benzoxazoles; Male; Migraine Disorders; Naphthyridines; Orexin R | 2021 |
Investigating the role of the amygdala orexin receptor 1 in memory acquisition and extinction in a rat model of PTSD.
Topics: Amygdala; Animals; Anxiety; Behavior, Animal; Benzoxazoles; Disease Models, Animal; Elevated Plus Ma | 2020 |
Hippocampal orexin receptor blocking prevented the stress induced social learning and memory deficits.
Topics: Animals; Anxiety; Benzoxazoles; Hippocampus; Isoquinolines; Male; Maze Learning; Memory; Naphthyridi | 2019 |
The orexin-1 receptor antagonist SB-334867 attenuates anxiety in rats exposed to cat odor but not the elevated plus maze: an investigation of Trial 1 and Trial 2 effects.
Topics: Animals; Anxiety; Avoidance Learning; Behavior, Animal; Benzoxazoles; Disease Models, Animal; Dose-R | 2014 |
Attenuated orexinergic signaling underlies depression-like responses induced by daytime light deficiency.
Topics: Animals; Anxiety; Behavior, Animal; Benzoxazoles; Circadian Rhythm; Depression; Disease Models, Anim | 2014 |
Orexin A enhances locomotor activity and induces anxiogenic-like action in the goldfish, Carassius auratus.
Topics: Animals; Anxiety; Benzoxazoles; Carbolines; Diazepam; Emotions; Goldfish; Hypnotics and Sedatives; I | 2014 |
[Awake intubation with landiolol and dexmedetomidine in a patient with anxiety neurosis].
Topics: Anesthesia, General; Anxiety; Anxiety Disorders; Dexmedetomidine; Emergencies; Female; Hemostasis, S | 2014 |
The orexin-1 receptor antagonist SB-334867 decreases anxiety-like behavior and c-Fos expression in the hypothalamus of rats exposed to cat odor.
Topics: Analysis of Variance; Animals; Anxiety; Benzoxazoles; Cats; Disease Models, Animal; Gene Expression | 2015 |
Denial Defense Mechanism in Dialyzed Patients.
Topics: Adaptation, Psychological; Adult; Affect; Aged; Albumins; Anxiety; Calcium; Cohort Studies; Creatini | 2015 |
The role of trigeminal nucleus caudalis orexin 1 receptor in orofacial pain-induced anxiety in rat.
Topics: Animals; Anxiety; Benzoxazoles; Capsaicin; Disease Models, Animal; Exploratory Behavior; Facial Pain | 2016 |
SB-334867, an orexin receptor 1 antagonist, decreased seizure and anxiety in pentylenetetrazol-kindled rats.
Topics: Animals; Anxiety; Benzoxazoles; Dose-Response Relationship, Drug; Kindling, Neurologic; Male; Maze L | 2017 |
Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior.
Topics: Animals; Anxiety; Arginine Vasopressin; Behavior, Addictive; Benzoxazoles; Conditioning, Operant; Co | 2010 |
Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference.
Topics: Acoustic Stimulation; Alcohol Drinking; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Can | 2010 |
Hcrtr1 and 2 signaling differentially regulates depression-like behaviors.
Topics: Animals; Anxiety; Benzoxazoles; Choice Behavior; Depression; Disease Models, Animal; Immobility Resp | 2011 |
Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia.
Topics: Animals; Anxiety; Benzoxazoles; Bradycardia; Disease Models, Animal; Hypercapnia; Hypertension; Intr | 2012 |
Orexin-1 receptor antagonism fails to reduce anxiety-like behaviour in either plus-maze-naïve or plus-maze-experienced mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Benzoxazoles; Chlordiazepoxide; Intracellular Signaling Pepti | 2013 |
[The blood-cerebrospinal fluid ratio of urea hypobromite in nervous and mental disease].
Topics: Anxiety; Blood; Language; Mental Disorders; Psychotic Disorders; Urea | 1950 |
Neural correlates of speech anticipatory anxiety in generalized social phobia.
Topics: Adult; Anxiety; Brain; Brain Mapping; Carbamide Peroxide; Case-Control Studies; Drug Combinations; H | 2004 |
Anticonvulsant and anxiolytic activity of FrPbAII, a novel GABA uptake inhibitor isolated from the venom of the social spider Parawixia bistriata (Araneidae: Araneae).
Topics: Analysis of Variance; Animals; Anticonvulsants; Anxiety; Behavior, Animal; Bicuculline; Choice Behav | 2006 |
Health risks of urea formaldehyde foam insulation.
Topics: Anxiety; Building Codes; Canada; Facility Design and Construction; Formaldehyde; Humans; Urea | 1984 |
Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety.
Topics: Animals; Anxiety; Behavior, Animal; Chlordiazepoxide; Conditioning, Operant; Conflict, Psychological | 1995 |
Quality of life in peritoneal dialysis patients.
Topics: Adult; Aged; Anxiety; Attitude to Health; Depression; Female; Humans; Kidney Failure, Chronic; Male; | 1996 |
Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Chlordiazepoxide; Disease Models, Animal; I | 1996 |
Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Biological Availability; Cell Line; Cerebell | 1999 |
Open-field behavior of rats previously subjected to short-term hyperbilirubinemia with or without blood-brain barrier manipulations.
Topics: Animals; Anxiety; Bilirubin; Blood-Brain Barrier; Exploratory Behavior; Hyperbilirubinemia; Male; Mo | 1987 |
Psychological and bioclinical CHD risk factors. Quantitative differences between obese, normal and thin subjects.
Topics: Adult; Anxiety; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Coronary Disease; Depressio | 1974 |
Serum albumin and urea during states of anxiety and depression.
Topics: Anxiety; Depression; Humans; Serum Albumin; Urea | 1973 |
Reformation of the anterior chamber of the eye.
Topics: Acetazolamide; Anterior Chamber; Anxiety; Aqueous Humor; Cataract Extraction; Corneal Injuries; Dich | 1968 |